Published in Gastroenterology on July 01, 2002
New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol (2006) 1.17
Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr (2010) 1.15
Laparoscopic cholecystectomy in cirrhotics. JSLS (2013) 1.09
Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ (2010) 0.98
The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework. Transfus Med (2012) 0.86
Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care (2005) 0.85
The use of recombinant activated coagulation factor VII for spine surgery. Eur Spine J (2004) 0.85
Percutaneous interventions in the coagulopathic patient. Semin Intervent Radiol (2005) 0.83
Recombinant factor VIIa as haemostatic therapy in advanced liver disease. Blood Transfus (2012) 0.79
Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy. Dig Dis Sci (2009) 0.78
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings. Crit Care (2005) 0.78
Recombinant activated factor VIIa in a case of pregnancy with acute hepatic failure and massive blood loss. Med J Armed Forces India (2011) 0.75
Risk of Bleeding in End-Stage Liver Disease Patients Undergoing Cardiac Catheterization. Tex Heart Inst J (2015) 0.75
Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope. Arch Med Sci (2017) 0.75
A cerebrovascular event after single-dose administration of recombinant factor VIIa in a patient with esophageal variceal bleeding. Dig Dis Sci (2006) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl (2005) 2.35
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation (2012) 2.10
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology (2004) 2.01
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
Aggressive resection of hepatocellular carcinoma with right atrial involvement. Am Surg (2009) 1.66
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.56
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr Pract (2002) 1.45
Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol (2004) 1.43
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology (2004) 1.42
Racial disparity in New Orleans: a faith-based approach to an age-old problem. Surgery (2012) 1.40
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
The impact of videorecording on the quality of colonoscopy performance: a pilot study. Am J Gastroenterol (2010) 1.28
Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology (2005) 1.27
Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol (2007) 1.24
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol (2007) 1.15
Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol (2003) 1.14
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci (2008) 1.10
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis (2004) 1.09
NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology (2013) 1.08
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion (2006) 1.07
Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci (2005) 1.07
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology (2002) 1.05
Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am J Gastroenterol (2006) 1.04
Potential role for rFVIIa in transfusion medicine. Transfusion (2002) 1.04
Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep (2008) 1.03
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol (2011) 1.02
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology (2011) 0.98
Vitamin d deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep (2012) 0.96
Nurse-administered propofol versus midazolam and meperidine for upper endoscopy in cirrhotic patients. Am J Gastroenterol (2003) 0.94
Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol (2013) 0.94
Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci (2003) 0.94
Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep (2009) 0.93
Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol (2010) 0.93
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology (2013) 0.92
A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis (2005) 0.92
De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant (2013) 0.91
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg (2010) 0.91
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol (2010) 0.90
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90
What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol (2012) 0.89
Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation (2007) 0.89
Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep (2011) 0.89
Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology (2012) 0.88
Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol (2005) 0.88
Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg (2006) 0.88
Factors that predict short-term intensive care unit mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2013) 0.88
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87
Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol (2013) 0.85
Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol (2006) 0.85
Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time! Gastroenterology (2009) 0.85
Management of hepatitis C infection after liver transplantation. Drugs (2007) 0.85
Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl (2004) 0.85
Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol (2010) 0.85
Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation (2007) 0.85
Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One (2013) 0.84
Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Front Genet (2012) 0.84
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int (2013) 0.84
Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients. Transplantation (2016) 0.84